Eliem Therapeutics (ELYM) Competitors

Ovid Therapeutics (NASDAQ:OVID) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Does the MarketBeat Community favor OVID or ELYM?

Ovid Therapeutics received 336 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 70.55% of users gave Ovid Therapeutics an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote.

Company	Underperform	Outperform
Ovid Therapeutics	Outperform Votes 345 70.55%	Underperform Votes 144 29.45%
Eliem Therapeutics	Outperform Votes 9 56.25%	Underperform Votes 7 43.75%

Which has better earnings and valuation, OVID or ELYM?

Eliem Therapeutics has lower revenue, but higher earnings than Ovid Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$390K	567.52	-$52.34M	-$0.73	-4.27
Eliem Therapeutics	N/A	N/A	-$35.12M	N/A	N/A

Do insiders and institutionals have more ownership in OVID or ELYM?

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 13.3% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is OVID or ELYM more profitable?

Eliem Therapeutics has a net margin of 0.00% compared to Eliem Therapeutics' net margin of -10,691.14%. Ovid Therapeutics' return on equity of -13.32% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-10,691.14%	-53.62%	-37.76%
Eliem Therapeutics	N/A	-13.32%	-12.95%

Which has more volatility & risk, OVID or ELYM?

Ovid Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.36, suggesting that its share price is 136% less volatile than the S&P 500.

Does the media refer more to OVID or ELYM?

In the previous week, Ovid Therapeutics had 11 more articles in the media than Eliem Therapeutics. MarketBeat recorded 13 mentions for Ovid Therapeutics and 2 mentions for Eliem Therapeutics. Ovid Therapeutics' average media sentiment score of 0.69 beat Eliem Therapeutics' score of 0.08 indicating that Eliem Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eliem Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer OVID or ELYM?

Ovid Therapeutics presently has a consensus price target of $8.08, suggesting a potential upside of 160.75%. Given Eliem Therapeutics' higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Summary

Ovid Therapeutics beats Eliem Therapeutics on 9 of the 14 factors compared between the two stocks.